Novartis hikes sales and profit guidance for the year
Novartis has lifted its full-year outlook for both sales and profit, signaling continued momentum in its transformation into a more focused, higher-growth innovator. The Swiss drugmaker said stronger-than-expected demand across several flagship medicines, improving supply for its radioligand therapies, and ongoing cost discipline support a higher guidance range for revenue and core operating income this year.
The update underscores how the company’s strategic refocus—cemented by the spin-off of its generics unit Sandoz—has sharpened execution across a streamlined portfolio, while newer launches scale and recently de-risked manufacturing capacity comes online.
What’s driving the upgrade
– Broad-based product growth: Novartis continues to benefit from rising adoption of key brands in cardiovascular, immunology, neuroscience, and oncology. Heart-failure therapy Entresto remains a foundational driver given its established standard-of-care status, while cancer medicines such as Kisqali (HR+/HER2- breast cancer) and the multiple sclerosis treatment Kesimpta are expanding in both new and existing markets. Cosentyx, its IL-17 inhibitor for dermatology and rheumatology, has maintained durable share amid competitive pressure.
– Radioligand therapy ramp: Production and supply reliability for radioligand therapies have improved versus the constraints seen during early commercialization. That has helped Pluvicto, a treatment for certain forms of advanced prostate cancer, reach more eligible patients and capture pent-up demand. Novartis has invested in additional manufacturing capacity and redundancy for this platform, which remains a strategic growth pillar alongside Lutathera in neuroendocrine tumors.
– Margin expansion and cost discipline: The company continues to translate top-line growth into operating leverage. Ongoing productivity programs, portfolio pruning, and operating-model simplification post-Sandoz have supported margin expansion in innovative medicines, even as Novartis invests in launches and late-stage R&D.
– Currency and geographic mix: While foreign-exchange swings can be volatile, Novartis typically guides in constant currencies. The uplift reflects underlying operational performance rather than a transient FX tailwind.
Strategic context
Since separating Sandoz, Novartis has emphasized execution in a tighter set of therapeutic areas where it sees sustainable differentiation. The portfolio now leans more heavily on specialty medicines with defensible clinical profiles, including in cardio-renal-metabolic disease, immunology, neuroscience, and oncology. The company has sought to balance high-volume, chronic therapies such as Entresto and Kesimpta with earlier-launch assets that may broaden into earlier treatment lines over time.
Radioligand therapies remain a signature bet. After early supply setbacks industry-wide, Novartis has moved to expand capacity and secure critical isotopes to stabilize growth. If the platform scales reliably, it could become a meaningful, multi-indication franchise with attractive margins, though manufacturing remains complex and capital-intensive.
Implications for investors
A guidance hike generally signals management confidence in near-term demand and cost execution. For Novartis, the mix of drivers matters:
– Demand durability: Growth anchored in chronic, standard-of-care therapies can be stickier and less promotion-sensitive than launch-only spikes.
– Launch quality: Continued uptake for Kisqali, Kesimpta, and Pluvicto suggests that recent launches are resonating with prescribers and payers, supporting multi-year growth rather than one-off beats.
– Operating leverage: Margin gains confirm that the post-spin operating model can scale, which is key for sustaining double-digit earnings growth when revenue growth moderates.
Key watch items and risks
– Patent and pricing headwinds: Entresto has been selected for U.S. Medicare price negotiations under the Inflation Reduction Act, which could pressure U.S. pricing when negotiated rates take effect. Broader pricing dynamics in Europe also remain a structural headwind. Over the medium term, lifecycle management and mix shift will be critical to offsetting erosion.
– Competition: In immunology and oncology, intense competition from established and emerging mechanisms (e.g., other IL-17/IL-23 agents in dermatology, CDK4/6 rivals in breast cancer, and novel MS therapies) demands sustained clinical differentiation and real-world outcomes to protect share.
– Manufacturing reliability: Radioligand therapies depend on robust, tightly synchronized supply chains. Any disruptions could temper growth. Continued capacity build-out and redundancy are essential.
– Regulatory and clinical milestones: Label expansions, earlier-line indications, and readouts from late-stage programs can reshape the growth curve positively or negatively. Execution in filing strategies and global market access will influence the pace of uptake.
Capital allocation and outlook
With a cleaner balance sheet and steadier cash generation from its innovative portfolio, Novartis has emphasized a balanced capital allocation framework: investing in internal R&D and manufacturing, pursuing disciplined bolt-on deals to strengthen priority platforms, and returning excess capital through dividends and share buybacks. The raised guidance suggests room to continue that approach without compromising pipeline funding.
Bottom line
Novartis’s guidance increase reflects a combination of strong commercial execution across flagship brands, improved reliability in radioligand therapy supply, and disciplined cost management. While pricing and competitive pressures persist, the company’s focused portfolio and operating leverage provide a clearer line of sight to profitable growth. The task now is consistent: sustain demand for core assets, execute on launches and label expansions, and keep manufacturing resilient—particularly in complex platforms that are fast becoming central to the growth story.
